- Report
- August 2025
- 154 Pages
Global
From €2404EUR$2,650USD£2,072GBP
- Report
- February 2026
- 250 Pages
Global
From €4073EUR$4,490USD£3,511GBP
- Report
- July 2026
- 478 Pages
Global
From €5307EUR$5,850USD£4,574GBP
- Report
- January 2026
- 180 Pages
Global
From €4083EUR$4,500USD£3,518GBP
- Report
- January 2026
- 180 Pages
Global
From €4083EUR$4,500USD£3,518GBP
- Report
- January 2026
- 185 Pages
Global
From €4083EUR$4,500USD£3,518GBP
- Report
- April 2026
- 148 Pages
Global
From €3628EUR$3,999USD£3,127GBP
- Report
- June 2025
- 379 Pages
Global
From €4491EUR$4,950USD£3,870GBP
- Report
- April 2021
Global
From €817EUR$900USD£704GBP
- Report
- August 2023
- 336 Pages
Global
From €4219EUR$4,650USD£3,636GBP
- Report
- February 2024
- 85 Pages
North America
From €4309EUR$4,750USD£3,714GBP
- Report
- January 2025
- 140 Pages
Global
From €3584EUR$3,950USD£3,088GBP
- Report
- January 2025
- 187 Pages
Global
From €4532EUR$4,995USD£3,906GBP
- Report
- June 2025
- 198 Pages
Global
From €4491EUR$4,950USD£3,870GBP
- Drug Pipelines
- December 2022
- 148 Pages
Global
From €13604EUR$14,995USD£11,724GBP
- Report
- May 2018
- 106 Pages
Global
From €3175EUR$3,500USD£2,737GBP
- Report
- September 2025
- 101 Pages
Global
From €3500EUR$4,133USD£3,122GBP

The Oral Insulin market is a subset of the Endocrine and Metabolic Disorders Drugs market. It is composed of drugs that are taken orally to treat diabetes, a condition in which the body does not produce enough insulin or is unable to use the insulin it produces. Oral Insulin is a relatively new form of treatment, and is seen as a more convenient and less invasive alternative to traditional insulin injections. It is also seen as a potential solution to the problem of poor adherence to insulin therapy.
Oral Insulin is still in the early stages of development, and there are currently no approved oral insulin products on the market. However, several companies are researching and developing oral insulin products, and some have already completed clinical trials. Companies in the Oral Insulin market include Novo Nordisk, Sanofi, Eli Lilly, Merck, and Pfizer. Show Less Read more